A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19
Copyright © 2020 Massachusetts Medical Society..
BACKGROUND: Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking.
METHODS: We conducted an open-label, cluster-randomized trial involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. We randomly assigned clusters of contacts to the hydroxychloroquine group (which received the drug at a dose of 800 mg once, followed by 400 mg daily for 6 days) or to the usual-care group (which received no specific therapy). The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, defined by symptoms compatible with Covid-19 or a positive PCR test regardless of symptoms. Adverse events were assessed for up to 28 days.
RESULTS: The analysis included 2314 healthy contacts of 672 index case patients with Covid-19 who were identified between March 17 and April 28, 2020. A total of 1116 contacts were randomly assigned to receive hydroxychloroquine and 1198 to receive usual care. Results were similar in the hydroxychloroquine and usual-care groups with respect to the incidence of PCR-confirmed, symptomatic Covid-19 (5.7% and 6.2%, respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]). In addition, hydroxychloroquine was not associated with a lower incidence of SARS-CoV-2 transmission than usual care (18.7% and 17.8%, respectively). The incidence of adverse events was higher in the hydroxychloroquine group than in the usual-care group (56.1% vs. 5.9%), but no treatment-related serious adverse events were reported.
CONCLUSIONS: Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient. (Funded by the crowdfunding campaign YoMeCorono and others; BCN-PEP-CoV2 ClinicalTrials.gov number, NCT04304053.).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:384 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 384(2021), 5 vom: 04. Feb., Seite 417-427 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mitjà, Oriol [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 09.02.2021 Date Revised 09.02.2021 published: Print-Electronic ClinicalTrials.gov: NCT04304053 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2021801 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318556294 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318556294 | ||
| 003 | DE-627 | ||
| 005 | 20231225165608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2021801 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318556294 | ||
| 035 | |a (NLM)33289973 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mitjà, Oriol |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2021 | ||
| 500 | |a Date Revised 09.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04304053 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking | ||
| 520 | |a METHODS: We conducted an open-label, cluster-randomized trial involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. We randomly assigned clusters of contacts to the hydroxychloroquine group (which received the drug at a dose of 800 mg once, followed by 400 mg daily for 6 days) or to the usual-care group (which received no specific therapy). The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, defined by symptoms compatible with Covid-19 or a positive PCR test regardless of symptoms. Adverse events were assessed for up to 28 days | ||
| 520 | |a RESULTS: The analysis included 2314 healthy contacts of 672 index case patients with Covid-19 who were identified between March 17 and April 28, 2020. A total of 1116 contacts were randomly assigned to receive hydroxychloroquine and 1198 to receive usual care. Results were similar in the hydroxychloroquine and usual-care groups with respect to the incidence of PCR-confirmed, symptomatic Covid-19 (5.7% and 6.2%, respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]). In addition, hydroxychloroquine was not associated with a lower incidence of SARS-CoV-2 transmission than usual care (18.7% and 17.8%, respectively). The incidence of adverse events was higher in the hydroxychloroquine group than in the usual-care group (56.1% vs. 5.9%), but no treatment-related serious adverse events were reported | ||
| 520 | |a CONCLUSIONS: Postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient. (Funded by the crowdfunding campaign YoMeCorono and others; BCN-PEP-CoV2 ClinicalTrials.gov number, NCT04304053.) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Corbacho-Monné, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Ubals, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Alemany, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Suñer, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Tebé, Cristian |e verfasserin |4 aut | |
| 700 | 1 | |a Tobias, Aurelio |e verfasserin |4 aut | |
| 700 | 1 | |a Peñafiel, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Ballana, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez, Carla A |e verfasserin |4 aut | |
| 700 | 1 | |a Admella, Pol |e verfasserin |4 aut | |
| 700 | 1 | |a Riera-Martí, Núria |e verfasserin |4 aut | |
| 700 | 1 | |a Laporte, Pep |e verfasserin |4 aut | |
| 700 | 1 | |a Mitjà, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Clua, Mireia |e verfasserin |4 aut | |
| 700 | 1 | |a Bertran, Laia |e verfasserin |4 aut | |
| 700 | 1 | |a Sarquella, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Gavilán, Sergi |e verfasserin |4 aut | |
| 700 | 1 | |a Ara, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Argimon, Josep M |e verfasserin |4 aut | |
| 700 | 1 | |a Cuatrecasas, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Cañadas, Paz |e verfasserin |4 aut | |
| 700 | 1 | |a Elizalde-Torrent, Aleix |e verfasserin |4 aut | |
| 700 | 1 | |a Fabregat, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Farré, Magí |e verfasserin |4 aut | |
| 700 | 1 | |a Forcada, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Flores-Mateo, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a López, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Muntada, Esteve |e verfasserin |4 aut | |
| 700 | 1 | |a Nadal, Núria |e verfasserin |4 aut | |
| 700 | 1 | |a Narejos, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Nieto, Aroa |e verfasserin |4 aut | |
| 700 | 1 | |a Prat, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a Puig, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Quiñones, Carles |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez-Viaplana, Ferran |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes-Urueña, Juliana |e verfasserin |4 aut | |
| 700 | 1 | |a Riveira-Muñoz, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Sergi |e verfasserin |4 aut | |
| 700 | 1 | |a Sentís, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Sierra, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Velasco, César |e verfasserin |4 aut | |
| 700 | 1 | |a Vivanco-Hidalgo, Rosa M |e verfasserin |4 aut | |
| 700 | 1 | |a Zamora, Juani |e verfasserin |4 aut | |
| 700 | 1 | |a Casabona, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Vall-Mayans, Martí |e verfasserin |4 aut | |
| 700 | 1 | |a González-Beiras, Camila |e verfasserin |4 aut | |
| 700 | 1 | |a Clotet, Bonaventura |e verfasserin |4 aut | |
| 700 | 0 | |a BCN-PEP-CoV2 Research Group |e verfasserin |4 aut | |
| 700 | 1 | |a Tuldrà, Albert |e investigator |4 oth | |
| 700 | 1 | |a Serrano, Xavi |e investigator |4 oth | |
| 700 | 1 | |a Uría, Estefany |e investigator |4 oth | |
| 700 | 1 | |a Herrero, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Gel, Sílvia |e investigator |4 oth | |
| 700 | 1 | |a Alomar, Alberto |e investigator |4 oth | |
| 700 | 1 | |a Esteve, Ricard |e investigator |4 oth | |
| 700 | 1 | |a Soley, Anna Maria |e investigator |4 oth | |
| 700 | 1 | |a Muntaner-Virgili, Clara |e investigator |4 oth | |
| 700 | 1 | |a Hueso-Mor, Alejandro |e investigator |4 oth | |
| 700 | 1 | |a Calvo, Laura |e investigator |4 oth | |
| 700 | 1 | |a Gamboa, Itziar |e investigator |4 oth | |
| 700 | 1 | |a Garcia-Diaz, Anna I |e investigator |4 oth | |
| 700 | 1 | |a Griñan, Kilian |e investigator |4 oth | |
| 700 | 1 | |a Castells-Büchle, Sara |e investigator |4 oth | |
| 700 | 1 | |a Alonso-Vallés, Alex |e investigator |4 oth | |
| 700 | 1 | |a Rebato, Carolina |e investigator |4 oth | |
| 700 | 1 | |a Juan, Mercè |e investigator |4 oth | |
| 700 | 1 | |a Palacín, Dolors |e investigator |4 oth | |
| 700 | 1 | |a López, José |e investigator |4 oth | |
| 700 | 1 | |a Molas, Elisenda |e investigator |4 oth | |
| 700 | 1 | |a Serra, Anna |e investigator |4 oth | |
| 700 | 1 | |a Sarrà, Sílvia |e investigator |4 oth | |
| 700 | 1 | |a Fericgla, Enric |e investigator |4 oth | |
| 700 | 1 | |a Latorre, Laura |e investigator |4 oth | |
| 700 | 1 | |a Turmo, Guillem |e investigator |4 oth | |
| 700 | 1 | |a López, Rosa |e investigator |4 oth | |
| 700 | 1 | |a Villa, Vanesa |e investigator |4 oth | |
| 700 | 1 | |a Martín, Laura |e investigator |4 oth | |
| 700 | 1 | |a Aragón, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Vilageli, Mireia |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Paula |e investigator |4 oth | |
| 700 | 1 | |a Naqui, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Judith |e investigator |4 oth | |
| 700 | 1 | |a Puche, Paula |e investigator |4 oth | |
| 700 | 1 | |a Yana, Emma |e investigator |4 oth | |
| 700 | 1 | |a Urrea, Magalí |e investigator |4 oth | |
| 700 | 1 | |a Barjau, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Utrillo, Roser |e investigator |4 oth | |
| 700 | 1 | |a Torra, Joan Enric |e investigator |4 oth | |
| 700 | 1 | |a Gilabert, Marta |e investigator |4 oth | |
| 700 | 1 | |a Domènech, Carme |e investigator |4 oth | |
| 700 | 1 | |a Cartiel, Judit |e investigator |4 oth | |
| 700 | 1 | |a López, Israel |e investigator |4 oth | |
| 700 | 1 | |a Pérez, Olga |e investigator |4 oth | |
| 700 | 1 | |a Rosell, Santiago |e investigator |4 oth | |
| 700 | 1 | |a Cobarsi, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Miranda, Cristina |e investigator |4 oth | |
| 700 | 1 | |a López, Míriam |e investigator |4 oth | |
| 700 | 1 | |a Martínez, Anna |e investigator |4 oth | |
| 700 | 1 | |a Jou, Toni |e investigator |4 oth | |
| 700 | 1 | |a Segundo, Cristina |e investigator |4 oth | |
| 700 | 1 | |a López, Nalia |e investigator |4 oth | |
| 700 | 1 | |a Estany, Carla |e investigator |4 oth | |
| 700 | 1 | |a Paris, Deborah |e investigator |4 oth | |
| 700 | 1 | |a Clemares, Sonia |e investigator |4 oth | |
| 700 | 1 | |a Teruel, Lara |e investigator |4 oth | |
| 700 | 1 | |a Romaní, Jorge |e investigator |4 oth | |
| 700 | 1 | |a Mateu, Lourdes |e investigator |4 oth | |
| 700 | 1 | |a Paredes, Roger |e investigator |4 oth | |
| 700 | 1 | |a Grau, Eulàlia |e investigator |4 oth | |
| 700 | 1 | |a Ramírez, Cristian |e investigator |4 oth | |
| 700 | 1 | |a Cabrera, Cecilia |e investigator |4 oth | |
| 700 | 1 | |a Cunyat, Francesc |e investigator |4 oth | |
| 700 | 1 | |a Badia, Roger |e investigator |4 oth | |
| 700 | 1 | |a Senserrich, Jordi |e investigator |4 oth | |
| 700 | 1 | |a Jordán, Ana |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez, M Lluïsa |e investigator |4 oth | |
| 700 | 1 | |a Tarrés, Ferran |e investigator |4 oth | |
| 700 | 1 | |a Ávila, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Bayón, Àngel |e investigator |4 oth | |
| 700 | 1 | |a Ortiz, Raquel |e investigator |4 oth | |
| 700 | 1 | |a Barajas, Ana |e investigator |4 oth | |
| 700 | 1 | |a Pedreño, Sònia |e investigator |4 oth | |
| 700 | 1 | |a Albacar, Emma |e investigator |4 oth | |
| 700 | 1 | |a Núñez, Xavier |e investigator |4 oth | |
| 700 | 1 | |a Vinyeta, Roger |e investigator |4 oth | |
| 700 | 1 | |a Caritg, Norma |e investigator |4 oth | |
| 700 | 1 | |a Bosch, Rosa |e investigator |4 oth | |
| 700 | 1 | |a Martí, Natàlia |e investigator |4 oth | |
| 700 | 1 | |a Castro, Paola |e investigator |4 oth | |
| 700 | 1 | |a Monset, Lluís |e investigator |4 oth | |
| 700 | 1 | |a Molera, Dolors |e investigator |4 oth | |
| 700 | 1 | |a Bermúdez, Dagda |e investigator |4 oth | |
| 700 | 1 | |a Moliner, Clara |e investigator |4 oth | |
| 700 | 1 | |a Tobajas, Gemma |e investigator |4 oth | |
| 700 | 1 | |a Bolívar-Prados, Mireia |e investigator |4 oth | |
| 700 | 1 | |a Clavé, Pere |e investigator |4 oth | |
| 700 | 1 | |a Egea-Cortés, Laia |e investigator |4 oth | |
| 700 | 1 | |a Díaz, Yesika |e investigator |4 oth | |
| 700 | 1 | |a Moreno-Fornés, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Montoro-Fernández, Marcos |e investigator |4 oth | |
| 700 | 1 | |a Velasco-Regúlez, Borja |e investigator |4 oth | |
| 700 | 1 | |a Domínguez, Didier |e investigator |4 oth | |
| 700 | 1 | |a Pons, Lourdes |e investigator |4 oth | |
| 700 | 1 | |a Becerra, Juan Carlos |e investigator |4 oth | |
| 700 | 1 | |a Diaz Soler, Esther |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 384(2021), 5 vom: 04. Feb., Seite 417-427 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:384 |g year:2021 |g number:5 |g day:04 |g month:02 |g pages:417-427 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2021801 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 384 |j 2021 |e 5 |b 04 |c 02 |h 417-427 | ||